Transient Ischemic Attack clinical trials
13 active trials name this condition. Describe your situation to see which ones you may be eligible for.
By location
- A Closed Loop Neural Activity Triggered Stroke Rehabilitation Device
- Somatic Dysfunction in Patients With Acute Cerebrovascular Disease
- Implementation of Onsite Rapid CYP2C19 Assay for Genotype Guided Dual Antiplatelet Therapy After Acute Ischemic Stroke
- Platelet Expression of FcγRIIa and Arterial Hemodynamics to Predict Recurrent Stroke in Intracranial Atherosclerosis
- Natural History of Stroke: Cause and Development
- Health Electronic Assessment of Risks and Trends Using Biometric Equipment and Technology
- Get With the Guidelines-Stroke Registry
- Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing
- The Neuralert Stroke Monitor Pilot Trial
- Cilostazol for Prevention of Recurrent Stroke Trial
- Focal Cerebral Arteriopathy Steroid Trial
- A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
- Improving Blood Pressure Control in Stroke Patients by Increasing Access to a Home Blood Pressure Monitor
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Transient Ischemic Attack” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.